Dick Fiona, Johanson Gard Aasmund Skulstad, Tysnes Ole-Bjørn, Alves Guido, Dölle Christian, Tzoulis Charalampos
Neuro-SysMed Center of Excellence for Clinical Research in Neurological Diseases, Department of Neurology, Haukeland University Hospital, 5021, Bergen, Norway.
Department of Clinical Medicine, University of Bergen, Pb 7804, 5020, Bergen, Norway.
Mol Neurobiol. 2025 Mar;62(3):2801-2816. doi: 10.1007/s12035-024-04422-y. Epub 2024 Aug 21.
The molecular pathogenesis of degenerative parkinsonisms, including Parkinson's disease (PD), progressive supranuclear palsy (PSP), and Multiple system atrophy (MSA), remains largely unknown. To gain novel insight into molecular processes associated with these diseases, we conducted a proteome-wide expression study in prefrontal cortex tissue from a cohort of 181 individuals, comprising PD (N = 73), PSP (N = 18), MSA (N = 17) and healthy control (N = 73). Using marker gene profiles, we first assess the cellular composition of the samples and, subsequently, identify distinct protein signatures for each disease, while correcting for cell composition. Our findings indicate that all three diseases are characterized by a structural and/or functional loss of deep cortical neurons, while PD exhibits an additional decrease in somatostatin-expressing interneurons, as well as in endothelial cells. Differential protein expression analysis identified multiple proteins and pathways with disease-specific expression, some of which have previously been associated with parkinsonism or neurodegeneration in general. Notably, we observed a strong mitochondrial signature which was present in both PD and PSP, albeit of a different composition and most pronounced in PSP, but not in MSA where immunological/inflammation-related pathways dominated. Additionally, we identified protein signatures associated with the severity of α-synuclein pathology in PD and showed that these are highly enriched in an upregulation of mitochondrial processes, specifically related to oxidative phosphorylation and in particular respiratory complexes I and IV. We identify multiple novel signatures of protein expression, associated with PD, PSP, and MSA, as well as with the severity of α-synuclein pathology in the PD brain.
包括帕金森病(PD)、进行性核上性麻痹(PSP)和多系统萎缩(MSA)在内的退行性帕金森综合征的分子发病机制在很大程度上仍不清楚。为了深入了解与这些疾病相关的分子过程,我们对181名个体的前额叶皮质组织进行了全蛋白质组表达研究,其中包括PD患者(N = 73)、PSP患者(N = 18)、MSA患者(N = 17)和健康对照者(N = 73)。利用标记基因谱,我们首先评估样本的细胞组成,随后在校正细胞组成的同时,识别每种疾病独特的蛋白质特征。我们的研究结果表明,所有这三种疾病的特征都是深层皮质神经元的结构和/或功能丧失,而PD患者中表达生长抑素的中间神经元以及内皮细胞数量额外减少。差异蛋白质表达分析确定了多种具有疾病特异性表达的蛋白质和通路,其中一些此前一般与帕金森综合征或神经退行性变有关。值得注意的是,我们观察到一种强烈的线粒体特征,它在PD和PSP中均存在,尽管组成不同且在PSP中最为明显,但在以免疫/炎症相关通路为主的MSA中不存在。此外,我们确定了与PD中α-突触核蛋白病理学严重程度相关的蛋白质特征,并表明这些特征在与氧化磷酸化特别是呼吸链复合体I和IV相关的线粒体过程上调中高度富集。我们识别出了与PD、PSP和MSA以及PD大脑中α-突触核蛋白病理学严重程度相关的多种蛋白质表达新特征。